Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

TWi Biotechnology completes patient enrollment in AC-201 phase II trial TWi Biotechnology has completed enrolling patients with acute arthritis of primary gout and elevated serum uric acid in AC-201 phase II trial for gout flare prophylaxis (GFP) during urate-lowering therapy (ULT). Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

TWi Biotechnology completes patient enrollment in AC-201 phase II trial
18 June 2013 | By PBR Staff Writer
TWi Biotechnology has completed enrolling patients with acute arthritis of primary gout and elevated serum uric acid in AC-201 phase II trial for gout flare prophylaxis (GFP) during urate-lowering therapy (ULT).
Contract Research & Services > Clinical Trials > News
Novartis' Jakavi demonstrates overall survival of myelofibrosis patients
17 June 2013 | By PBR Staff Writer
Novartis' investigational drug, Jakavi, has demonstrated improvement in overall survival of myelofibrosis patients with continuation of spleen size reductions compared to conventional therapy.
Contract Research & Services > Clinical Trials > News

Contract Research

Civitas wins second MJFF grant to advance CVT-301 research
19 June 2013
The Michael J. Fox Foundation for Parkinson's Research (MJFF) has announced a second grant to Civitas Therapeutics to advance the research of its lead product CVT-301.
Contract Research & Services > Contract Research > News
NGM, AstraZeneca’s MedImmune partner to develop Diabetes and Obesity therapies
17 June 2013 | By PBR Staff Writer
US-based drug discovery company NGM Biopharma and AstraZeneca’s Biologics unit MedImmune have agreed to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell (EEC) program to treat type 2 diabetes and obesity.
Contract Research & Services > Contract Research > News

Contract Services

T3D Therapeutics wins exclusive global rights to DB959 from DARA BioSciences
19 June 2013 | By PBR Staff Writer
T3D Therapeutics has obtained exclusive global rights to develop and commercialize oral, highly selective, dual nuclear receptor agonist DB959 from DARA BioSciences.
Contract Research & Services > Contract Services > News
Eli Lilly exercises rights to type 2 diabetes drug under deal with Transition Therapeutics
19 June 2013 | By PBR Staff Writer
Eli Lilly and Company has opted to presume all development and commercialization rights to type 2 diabetes drug candidate, TT-401, under the deal with Transition Therapeutics.
Contract Research & Services > Contract Services > News